Mauna Kea Technologies, page-19

Oh, I thought you were questioning the valuation. Sure, there is risk, and still a couple of years before revenues from all the tech can happen. However, the SP increase from single digits and now above 0.20 is due to the reduced risk now since the Mayo clinic collaboration announcement, and other announcements around the digital pathology tech developments getting closer to being a reality. Is it possible the SP will retrace back to the teens, or even single digits? Sure. Is it just as likely a partnership is announced, alluded to in an announcement a few weeks ago? I think so. The AI integration software is close to being finalised (in the next 6 months if the timeline is met). Again, if none of that makes sense, I suggest you do more DD and try and work out if all the developments align with you valuation. At moment, the market has it at 0.20+.